

CURRICULUM VITAE

MICHAEL ROBERT HORSMAN

Født 3. december, 1953, London, England
Nationalitet Britisk
Privatadresse Jernaldervej 300, 8210 Aarhus V, Danmark

Uddannelser

1959-1965 Michael Faraday Primary and Junior School, London, England
1965-1973 Archbishop Tenison's Grammar School, London England
1974-1977 Oxford Polytechnic, Oxford, England
1977-1980 University of London, Sutton, Surrey, England

Akademiske grader

1977 B.Sc. (Hons) i humanbiologi
1981 Ph.d. i strålebiologi
1996 Dr.Med i sundhedsvidenskab

Nuværende ansættelse

Professor i eksperimental strålebehandling, Afdeling for Eksperimentel Klinisk Onkologi, Aarhus Universitetshospital, Nørrebrogade 44, 8000 Aarhus C (2012-nu).

Tidligere forskerstillinger

1977-1980 Ph.d.-studerende, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, England.
1981-1986 Forskningslektor, Department of Therapeutic Radiology, Division of Radiobiology Research, Stanford University, Stanford, California, USA
1987-1989 Forsker, Kræftens Bekæmpelse, Afdeling for Eksperimentel Klinisk Onkologi, Aarhus, Danmark
1990-1997 Seniorforsker, Kræftens Bekæmpelse, Afdeling for Eksperimentel Klinisk Onkologi, Aarhus, Danmark
1997-2012 Lektor, Aarhus Universitet, Danmark

Priser og udmærkelser

The 11th Annual Robert F. Kallman Memorial Lecture (2014)
The Order of St. John Fellowship Anniversary Silver Medal Award (2013)
The B.B. Singh Oratory (2012)
Winner of the ESHO-BSD Award (2011)
The Martin Lindgren Lecture (1998)
Winner of the 1988 Lund Science Award
Conference on Chemical Modifiers of Cancer Treatment, Junior Investigator Award, Clearwater, FL, USA, October (1985)
CROS Conference on Chemical Modifiers of Cancer Treatment, Junior Investigator Award, Banff, Alberta, Canada, December (1983)
Seventh International Congress on Radiation Research, Junior Investigator Award, Amsterdam, The Netherlands, July (1983)
CROS Conference on Chemical Modification : Radiation and Cytotoxic Drugs, Junior Investigator Award, Key Biscayne, FL, USA, September (1981)
Radiation Research Society Student Travel Award, New Orleans, LA, USA, May (1980)

Publikationer og præsentationer

Antal publikationer: 253, Peer-revied artikler: 163, Bogkapitler: 37,
H-index: 44, Antal citationer: 5615, Præsentationer ved videnskabelige møder (oral): 155.

Udvalgs- og bestyrelsesposter

Sekretær ved General and Scientific Secretary of the European Society for Hyperthermic Oncology (2013-)
Medlem af bestyrelsen for the European Society for Hyperthermic Oncology (2003-2006, 2008-2011, 2013-)
Bestyrelsesmedlem af Dansk Selskab for Cancerforskning (2005-2008)
Sekretær/kasserer ved the International Association for Hyperthermic Oncology (2004-2008)

Vejledning

Vejleder for 12 Ph.d.-studerende ved Health, Aarhus Universitet, Danmark

Vejleder for 1 Ph.d.-studerende ved Medical Faculty, University of Turku

Vejleder for 3 diplomstuderende ved Health, Aarhus Universitet, Danmark

Vejleder for 1 MSc studerende ved School of Pharmacology, University of Bath, England

Bedømmelser

MIDTVEJS KVALIFICERENDE EKSAMINER FOR PH.D.:

2 studenter ved Science and Technology, Aarhus Universitet, Danmark

Ph.D. AFHANDLINGER:

1 student ved Health, Aarhus Universitet, Danmark

1 student ved University of Lund, Sverige

2 studenter ved University of London, Storbritannien

1 student ved University of Padova, Italien

1 student ved University of British Columbia, Canada

1 student ved Københavns Universitet, Danmark

1 student ved University of Oslo, Norge

M.Sc. AFHANDLINGER:

1 student ved University of Aukland, New Zealand

1 student ved Health, Aarhus Universitet, Danmark

1 student ved Syddansk Universitet, Danmark

Dr. PHILOS AFHANDLINGER:

6 studenter ved University of Oslo, Norge

D.M.Sc. AFHANDLINGER:

1 student ved Københavns Universitet, Danmark

2 studenter ved University of Bergen, Norge

M.D. AFHANDLINGER:

1 student ved University of London, Storbritannien

Større forskningsbevillinger

Kræftens Bekæmpelse: Identifying and targeting the different microenvironmental and vascular features of tumours to improve radiotherapy outcome (2012-2014)

Therapeutic impact of the tumour microenvironment and vasculature (2008-2010)

Det Frie Forskningsråd | Sundhed og Sygdom: Bioimaging of tumour hypoxia to improve the therapeutic outcome in cancer patients (2006-2008)

Det Frie Forskningsråd | Sundhed og Sygdom: Improving cancer therapy by targeting the tumour vasculature: Optimizing and exploiting novel and established approaches (2010-2012)

Ekstern bedømmer for fonde

Association for International Cancer Research

AstraZeneca Research and Educational Scholarships

Belgian Foundation Against Cancer

Dutch Cancer Society

Flanders Research Foundation

Flight Attendant Medical Research Institute

Health Research Council of New Zealand

Medical Research Council of Canada

NATO Collaborative Research Grants

Shota Rustaveli National Science Foundation of Georgia

U.K. Cancer Research Campaign

University of Antwerp Research Council

Organisering af møder

Medlem af the Organising Committee of the Tumour Hypoxia Meeting, April 9-11, 1986, Vancouver, British Columbia, Canada.

Medlem af the Organising Committee for the COMAC-BME Workshop on Clinical Evaluation of Hyperthermia, February 23-25, 1990, Copenhagen, Denmark.

Medlem af the Organising Committee of the 3rd International Workshop on Tumor Hypoxia, July 2-5, 1991, Orillia, Ontario, Canada.

Arrangør af the Workshop on The Potential of NMR Spectroscopy for In Vivo Cancer Research, April 26-27, 1993, Aarhus, Denmark.

Medlem af the Scientific Committee of the 13th Annual Conference of the European Society for Hyperthermic Oncology, June 16-19, 1993, Brussels, Belgium.

Formand for the Organising Committee of the International Workshop on Tumour Microenvironment: Its Characterization, Modification and Clinical Implications, September 23-25, 1994, Granada, Spain.

Medlem af the Scientific Programme Committee of the 3rd International ARCON Workshop, August 14-17, 1996, Umeå, Sweden.

Medlem af the Organizing Committee of the International Workshop on the Tumor Microenvironment: An Important Paradigm in Cancer Etiology and Treatment, April 28 - May 2, 1997, Martha's Vineyard, RI, USA.

Medlem af the Programme Committee of the 10th International Conference on Chemical Modifiers of Cancer Treatment, January 28-31, 1998, Clearwater, FL, USA.

Med-arrangør af the Workshop on Non-invasive Imaging of Tumour Hypoxia, November 21, 1998, Aarhus, Denmark.

Arrangør af the Danish Society for Cancer Research Meeting on "Damaging established tumour vasculature: an alternative to anti-angiogenesis approaches", August 25, 1999, Copenhagen, Denmark.

Medlem af the Scientific Committee of the 18th Annual Meeting of the European Society for Hyperthermic Oncology, September 1-4, 1999, Rotterdam, The Netherlands.

Medlem af the Organizing Committee of the NOS-M Symposium on Angiogenesis, January 7-9, 2000, Gentofte Denmark.

Medlem af the Scientific Committee of the 8th International Congress of Hyperthermic Oncology, April 26-29, 2000, Kyong-Ju, Korea.

Medlem af the Programme Committee of the 19th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 17-21, 2000, Istanbul, Turkey.

Medlem af the Faculty of the 11th International Conference on Chemical Modifiers of Cancer Treatment, October 5-7, 2000, Banff, Alberta, Canada.

Medlem af the Organizing Committee of the 7th International Workshop on the Tumor Microenvironment and Its Impact on Cancer Therapies, April 19-21, 2001, Atlanta, GA, USA.

Medlem af the Scientific Committee of the 19th Annual Meeting of the European Society for Hyperthermic Oncology, May 30 - June 2, 2001, Verona, Italy.

Arrangør og formand for the Scientific Programme Committee of the 1st ESTRO Workshop on Biology in Radiation Oncology, June 10-12, 2001, Fuglsø, Denmark.

Medlem af the Organizing Committee of the 8th International Workshop on the Tumor Microenvironment and Its Impact on Cancer Therapies, May 3-7, 2003, Miami, FL, USA.

Medlem af the Scientific Committee of the 2nd ESTRO Workshop on Biology in Radiation Oncology, June 1-3, 2003, Nijmegen, The Netherlands.

Medlem af the Scientific Programme Committee of the 9th International Congress on Hyperthermic Oncology, April 20-24, 2004, St. Louis, MO, USA.

Medlem af the Scientific Radiobiology Committee of the 23rd Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September, 2004, Amsterdam, The Netherlands.

Medlem af the programme Committee for the 18th Annual Meeting of the Danish Society for Cancer Research, May 4, 2005, Vilvorde, Denmark.

Medlem af the Scientific Committee of the 22nd Annual Meeting of the European Society for Hyperthermic Oncology, June 8-11, 2005, Graz, Austria.

Medlem af the Organizing Committee of the 9th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, August 20-23, 2005, Oxford, UK.

Medlem af the programme Committee for the 19th Annual Meeting of the Danish Society for Cancer Research, May 5, 2006, Vilvorde, Denmark.

Medlem af the Organizing Committee of the 10th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, September 15-18, 2006, Boston, USA.

Medlem af the Programme Committee for the 20th Annual Meeting of the Danish Society for Cancer Research, May 11, 2007, Vilvorde, Denmark.

Med-arrangør af the 3rd European Society for Hyperthermic Oncology Educational Day, June 13, 2007, Prague, Czech Republic.

Medlem af the Programme Committee for the 21st Annual Meeting of the Danish Society for Cancer Research, April 30, 2008, Vilvorde, Denmark.

Medlem af the Organizing Committee of the 11th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 15-17, 2008, Miami, USA.

Medlem af the Scientific Committee of the International Conference on Tumor hypoxia and malignant progression, October 1-4, 2008, Kiev, Ukraine.

Medlem af the Organizing Committee of the 12th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 2-5, 2010, Toronto, Canada.

Medlem af the International Scientific Programme Committee of the International Conference on Tumor and Host: novel aspects of old problem, September 21-24, 2010, Kiev, Ukraine.

Arrangør af the 7th European Society for Hyperthermic Oncology Educational Day, May 25, 2011, Aarhus, Denmark.

Arrangør af the 27th Annual Meeting of the European Society for Hyperthermic Oncology, May 26-28, 2011, Aarhus, Denmark.

Medlem af the Scientific Committee of the 12th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology, June 25-27, 2011, Ermatingen, Switzerland.

Medlem af the Organizing Committee of the Aarhus PET-MR Hybrid Scanner Workshop on Instrumentation, Development, Research and Clinical Application, June 29, 2011, Aarhus, Denmark.

Medlem af the Organizing Committee of the 13th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 2-4, 2013, Miami, USA.

Medlem af the Local Organizing Faculty of the 11th Acta Oncologica Symposium BiGART 2013, June 11-13, 2013, Aarhus, Denmark.

Medlem af the Scientific Committee of the 28th Annual Meeting of the European Society for Hyperthermic Oncology, June 19-22, 2013, Munich, Germany.

Medlem af Board of Directors of the European Society for Hyperthermic Oncology School on Hyperthermia & Thermal Ablation in Cancer Therapy, February 3-6, 2014, Huntsham, UK.

Medlem af the Scientific Committee of the 29th Annual Meeting of the European Society for Hyperthermic Oncology, June 11-14, 2014, Torino, Italy.

Medlem af the Local Organizing Faculty of the 12th Acta Oncologica Symposium BiGART 2015, June 10-12, 2015, Aarhus, Denmark.

Medlem af the Scientific Committee of the 30th Annual Meeting of the European Society for Hyperthermic Oncology, June 24-27, 2015, Zurich, Switzerland.

Medlem af the Organizing Committee of the 14th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, August 27-29, 2015, Vancouver, Canada.

Medlem af the Organizing Committee of the 15th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, April 27-29, 2017, Miami, USA.

Medlem af the Local Organizing Faculty of the 13th Acta Oncologica Symposium BiGART 2017, June 13-16, 2017, Aarhus, Denmark.

Medlem af the Scientific Committee of the 31st Annual Meeting of the European Society for Hyperthermic Oncology, June 21-23, 2017, Athens, Greece.

Mødeledelse

Mødeleder ved the Session on Hypoxic Cell Sensitizers I, at the 34th Annual Radiation Research Society Meeting, April 12-17, 1986, Las Vegas, NV, USA.

Mødeleder ved the Session on Immunology and Physiological Effects, at the 37th Annual Radiation Research Society Meeting, March 19-23, 1989, Seattle, WA, USA.

Arrangør og mødeleder ved the Workshop on Vascular and Environmental Effects of Hyperthermia, at the 10th Annual European Society for Hyperthermic Oncology Meeting, September 21-23, 1989, Amsterdam, The Netherlands.

Mødeleder ved the Session on Tumor Hypoxia - Impact on Radiation Response, at the 3rd International Workshop on Tumor Hypoxia, July 2-5, 1991, Orillia, Ontario, Canada.

Mødeleder ved the Workshop on Bioreductive Drugs, Sensitizers, Oxygen, and Radiation, October 20-22, 1991, Vienna, Austria.

Arrangør og mødeleder ved the Workshop on Tumour Physiology and the Response to Heat: Clinically Relevant Predictive Assays and Methods of Modification, at the 6th International Congress of Hyperthermic Oncology, April 26 - May 1, 1992, Tucson, AZ, USA.

Mødeleder ved the Workshop on The Potential of NMR Spectroscopy for In Vivo Cancer Research, April 26-27, 1993, Aarhus, Denmark.

Mødeleder ved the Session on Manipulation of Tumor Oxygen and Physiology, at the 8th International Conference on Chemical Modifiers of Cancer Treatment, June 16-19, 1993, Kyoto, Japan.

Mødeleder ved the Session on Preclinical Study, at the International Congress of Radiation Oncology - 1993, June 21-25, 1993, Kyoto, Japan.

Mødeleder ved the Workshop on The Tumour Microenvironment: Its Characterization, Modification and Clinical Implications, September 23-25, 1994, Granada, Spain.

Mødeleder ved the 9th International Conference on Chemical Modifiers of Cancer Treatment, August 22-26, 1995, Oxford, England.

Mødeleder ved the 15th Annual Meeting of the European Society for Hyperthermic Oncology, September 3-6, 1995, Oxford, England.

Arrangør og Mødeleder ved the Symposium on Clinical and Physical Advances on the Study of Tumor Micro-Environment and Clinical Heat Response, at the 7th International Congress of Hyperthermic Oncology, April 9-13, 1996, Rome, Italy.

Mødeleder ved the Session on Tumour Microenvironment at the 15th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 23-26, 1996, Vienna, Austria.

Mødeleder ved the Session on Cellular and Physiological Effects of Hyperthermia at the 16th Annual Meeting of the European Society for Hyperthermic Oncology, April 2-5, 1997, Berlin, Germany.

Mødeleder ved the Workshop on the Tumour Microenvironment: An Important Paradigm in Cancer Etiology and Treatment, April 28 - May 2, 1997, Martha's Vineyard, RI, USA.

Mødeleder ved the Session on Tumour Biology at the 17th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 20-24, 1998, Edinburgh, UK.

Mødeleder ved the Session on Oxidative Metabolism at the 8th Symposium on the Medical Applications of Cyclotrons, May 22-25, 1999, Turku, Finland.

Mødeleder ved the Session on Enhancing Therapy at the International Workshop on the Tumour Microenvironment, July, 15-17, 1999, Belfast, UK.

Mødeleder ved the Session on WBHT and Three-Modality at the 18th Annual Meeting of the European Society for Hyperthermic Oncology, September 1-4, 1999, Rotterdam, The Netherlands.

Mødeleder ved the 41st Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, October 31 - November 4, 1999, San Antonio, TX, USA.

Mødeleder ved the Session on Vasculature, Angiogenesis and Hypoxia at the First International Conference on Translational Research and Pre-Clinical Strategies in Radio-Oncology, March 5-8, 2000, Lugano, Switzerland.

Mødeleder ved at the 8th International Congress of Hyperthermic Oncology, April 26-29, 2000, Kyong-Ju, Korea.

Mødeleder ved the Session on Tumor Oxygenation/Physiology at the 11th International Conference on Chemical Modifiers of Cancer Treatment, October 5-7, 2000, Banff, Alberta, Canada.

Mødeleder ved the Session on Tumor Physiology and Treatment Outcome at the 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology, October 22-26, 2000, Boston, MA, USA.

Mødeleder ved the Session on Anti-Vascular/Anti-Angiogenic Therapies at the 7th International Workshop on The Tumour Microenvironment and Its Impact on Cancer Therapies, April 19-21, 2001, Atlanta, GA, USA.

Mødeleder ved the Session on Cellular and Physiological Mechanisms at the 19th Annual Meeting of the European Society for Hyperthermic Oncology, May 30-June 2, 2001, Verona, Italy.

Mødeleder ved the Session on Modifying Microenvironment at the 21st Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 17-21, 2002, Praha, Czech Republic.

Mødeleder ved the Teaching Lecture on Translational Research in Radiation Oncology at the 12th Annual Meeting of the European Cancer Congress, September 21-25, 2003, Copenhagen, Denmark.

Mødeleder ved the 9th Annual Scientific Meeting of the Sector for Clinical research, Dept. Oncology, Aarhus University Hospital, October 3-4, 2003, Fuglsøcentret, Mols, Denmark.

Mødeleder ved the Session on Low Molecular Weight Vascular Targeting Agents at the 2nd International Conference on Vascular Targeting, May 16-18, 2004, Miami, FL, USA.

Mødeleder ved the Session on Hypoxia and Angiogenesis at the 23rd Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September, 2004, Amsterdam, The Netherlands.

Mødeleder ved the Biology Session at the 22nd Annual Meeting of the European Society for Hyperthermic Oncology, June, 2005, Graz, Austria.

Mødeleder ved the 9th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, August 20-23, 2005, Oxford, UK.

Mødeleder ved the Session on Cell-Microenvironment at the 3rd International Conference on Translational Research and pre-clinical Strategies in Radiation Oncology, March 12-15, 2006, Lugano, Switzerland.

Mødeleder ved the Preclinical Research Session at the 23rd Annual Meeting of the European Society for Hyperthermic Oncology, May 24-27, 2006, Berlin, Germany.

Mødeleder ved the Characterisation Session at the 10th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, September 15-17, 2006, Boston, USA.

Mødeleder ved the Session on Vascular Targeting at the 24th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, October 8-12, 2006, Leipzig, Germany.

Mødeleder ved the Session on Mechanisms and experimental therapy at the 20th Annual Meeting of the Danish Association for Cancer Research, May 11, 2007, Vilvorde, Denmark.

Mødeleder ved the Session on Vascular mediated responses to heat at the 3rd European Society for Hyperthermic Oncology Educational Day, June 13, 2007, Prague, Czech Republic.

Mødeleder ved the Session on Biological Developments at the 24th Annual Meeting of the European Society for Hyperthermic Oncology, June 14-16, 2007, Prague, Czech Republic.

Mødeleder ved the Session on Physiological effects of Hyperthermia at the 10th International Congress on Hyperthermic Oncology, April 9-12, 2008, Munich, Germany.

Mødeleder ved the Session on Pathological Considerations at the 11th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 15-17, 2008, Miami, USA.

Mødeleder ved the Session on Hypoxia and Vasculature at the 25th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 14-18, 2008, Göteborg, Sweden.

Mødeleder ved the International Conference on Tumor hypoxia and malignant progression, October 1-4, 2008, Kiev, Ukraine.

Mødeleder ved the Session on Biological Imaging at the 4th International Conference on Translational Research and pre-clinical Strategies in Radiation Oncology, March 11-13, 2009, Geneva, Switzerland.

Mødeleder ved the Biological Session on Chemo-hyperthermia in disease progression at the 25th Annual Meeting of the European Society for Hyperthermic Oncology, June 4-6, 2009, Verona, Italy.

Mødeleder ved the Session on Angiogenesis and Cancer Therapies at the 25th Annual Meeting of the European Society for Hyperthermic Oncology, June 4-6, 2009, Verona, Italy.

Mødeleder ved the Session on Imaging and Therapy Predictions at the 12th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 2-5, 2010, Toronto, Canada.

Mødeleder ved the Session on Pathophysiological Effects at the 26th Annual Meeting of the European Society for Hyperthermic Oncology, May 20-22, 2010, Rotterdam, The Netherlands.

Mødeleder ved the Keynote Lecture on Thermotherapy with Magnetic Nanoparticles at the 27th Annual Meeting of the European Society for Hyperthermic Oncology, May 26-28, 2011, Aarhus, Denmark.

Mødeleder ved the Session on Establishing Hyperthermia in Australia at the 27th Annual Meeting of the European Society for Hyperthermic Oncology, May 26-28, 2011, Aarhus, Denmark.

Mødeleder ved the Session on Tumor Physiology, Therapy Response and Resistance at the 13th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 2-4, 2013, Miami, USA.

Mødeleder ved the Session on Biological Imaging Developments at the 11th Acta Oncologica Symposium BiGART 2013, June 11-13, 2013, Aarhus, Denmark.

Mødeleder ved the Session on Innovations and Targets at the 28th Annual Meeting of the European Society for Hyperthermic Oncology, June 19-22, 2013, Munich, Germany.

Mødeleder ved the Session on Biological Developments at the 29th Annual Meeting of the European Society for Hyperthermic Oncology, June 11-14, 2014, Torino, Italy.

Mødeleder ved the Session on Tumor Oxygenation: Impact on Cancer Therapy at the 60th Annual Meeting of the Radiation Research Society, September 21-24, 2014, Las Vegas, USA.

Mødeleder ved a poster session at the Aarhus University Graduate School of Health PhD Day, January 23, 2015, Aarhus, Denmark.

Mødeleder ved the Session on Radiosensitization at the 15th International Congress of Radiation Research, May 25-29, 2015, Kyoto, Japan.

Mødeleder ved the Session on Radiobiology of Human Tumors: Guidance for Therapy at the 13th Acta Oncologica Symposium BiGART 2015, June 10-12, 2015, Aarhus, Denmark.

Mødeleder ved the Biology Session at the 30th Annual Meeting of the European Society for Hyperthermic Oncology, June 24-26, 2015, Zurich, Switzerland.

Mødeleder ved the Session on Hypoxia: Imaging, Detection and Significance at the 14th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, August 27-29, 2015, Vancouver, Canada.

Mødeleder ved a poster session at the Aarhus University Graduate School of Health PhD Day, January 22, 2016, Aarhus, Denmark.

Mødeleder ved the Session on Emerging Hyperthermia Biology at the 12th International Congress on Hyperthermic Oncology, April 11-15, 2016, New Orleans, USA.

Mødeleder ved the Session on Imaging, Biomarkers and Therapeutic Prediction at the 15th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, April 27-29, 2017, Miami, USA.

Mødeleder ved the Poster Discussion Session on Radiobiological/Pre-clinical Studies at the 14th Acta Oncologica Symposium BiGART 2017, June 13-16, 2017, Aarhus, Denmark.

Mødeleder-vikar (pga. mødeleders sygdom) ved Educational Session 1 at the 31st Annual Meeting of the European Society for Hyperthermic Oncology, June 21-23, 2017, Athens, Greece.

Mødeleder ved Oral Presentation Session 5 at the 31st Annual Meeting of the European Society for Hyperthermic Oncology, June 21-23, 2017, Athens, Greece

Inviteret forelæser ved møder, konferencer og symposier

"Lund Science Award" Lecture, at the 5th International Congress of Hyperthermic Oncology, August 1988, Kyoto, Japan.

NATO Advanced Research Workshop on Selective Activation of Drugs by Redox Processes, August 1989, Fermo, Italy.

The 10th Annual European Society for Hyperthermic Oncology Meeting, September 1989, Amsterdam, The Netherlands.

EORTC Radiotherapy Group Consensus Meeting on Tumour Hypoxia, December 1989, Leuven, Belgium.

COMAC-BME Workshop on Clinical Evaluation of Hyperthermia, February 1990, Copenhagen, Denmark.

ARCON Workshop on Accelerated Radiotherapy with Carbogen/Oxygen and Nicotinamide, June 1991, Gray Laboratory, England.

The 12th Annual European Society for Hyperthermic Oncology Meeting, June 1991, Bergen, Norway.

Workshop on Bioreductive Drugs, Sensitizers, Oxygen, and Radiation, October 1991, Vienna, Austria.

Symposium on Treatment Resistance, Danish Society for Medical Oncology, January 1992, Helsingør, Denmark.

The 40th Annual Radiation Research Society Meeting, March 1992, Salt Lake City, UT, USA.

The 6th International Congress of Hyperthermic Oncology, April 1992, Tucson, AZ, USA.

The 11th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 1992, Malmö, Sweden.

Workshop on The Potential of NMR Spectroscopy for In Vivo Cancer Research, April 1993, Aarhus, Denmark.

The 2nd ARCON Workshop on Accelerated Radiotherapy with Carbogen and Nicotinamide, March 1994, Northwood, England.

The 2nd International Expert Meeting on Tumour Oxygenation, March 1994, Hamburg, Germany.

The 14th Annual European Society for Hyperthermia Oncology Meeting, June 1994, Amsterdam, The Netherlands.

Symposium in Honour of Lars-Gunnar Larsson's 75th Birthday, June 1994, Umeå, Sweden.

The 13th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 1994, Granada, Spain.

The 43rd Annual Radiation Research Society Meeting, April 1995, San Jose, CA, USA.

Symposium on Tumour Oxygenation and Radiotherapy, Academic Medical Center, February 1996, Amsterdam, The Netherlands.

The European Nuclear Medicine Congress, September 1996, Copenhagen, Denmark.

The 2nd International Conference on Redox Processes and Cancer: Molecular Biology and Therapeutics, April 1997, Banff, Alberta, Canada.

The 10th International Conference on Chemical Modifiers of Cancer Treatment, January 1998, Clearwater, FL, USA.

The 17th Annual North American Hyperthermia Society Meeting, April 1998, Louisville, KY, USA.

The Dr. Paul Janssen Medical Institute Symposium on Tumour Oxygenation, March 1999, Munich, Germany.

The 8th Symposium on the Medical Applications of Cyclotrons, May 1999, Turku, Finland.

The 18th Annual Meeting of the European Society for Hyperthermic Oncology, September 1999, Rotterdam, The Netherlands.

The Danish Society for Medical Oncology Annual Meeting, January 2000, Helsingør, Denmark.

The 19th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 2000, Istanbul, Turkey.

The Annual Meeting of the Belgium Society for Cancer Research, January 2001, Brussels, Belgium.

The 18th North American Hyperthermia Society Annual Scientific Meeting, April 2001, San Juan, Puerto Rico.

Scandinavian Congress in Clinical Physiology and Nuclear Medicine, April 2001, Aarhus, Denmark.

The 4th Nordic Conference on Radiation Oncology, June 2001, Aarhus, Denmark.
The 1st ESTRO Workshop on Biology in Radiation Oncology, June 2001, Fuglsø, Denmark.
The XI Congress of the Spanish Association for Radiotherapy and Oncology, October 2001, Murcia, Spain.
The Danish Society for Biochemistry and Molecular Biology Symposium on From Gas to Gene: Molecular Mechanism of Oxygen Sensing in Health and Disease, February 2002, Copenhagen, Denmark.
The Dansk Selskab for Onkologi Annual Meeting, April 2002, Middlefart, Denmark.
The 49th Annual Radiation Research Society Meeting, April 2002, Reno, NV, USA.
The 1st International Conference on Vascular Targeting, June 2002, Boston, MA, USA.
The 8th International Workshop on the Tumor Microenvironment and its Impact on Cancer Therapies, May 2003, Miami, FL, USA.
The 2nd ESTRO Workshop on Biology in Radiation Oncology, June 2003, Nijmegen, The Netherlands.
The 21st Annual Meeting of the European Society for Hyperthermic Oncology, June 2003, Munich, Germany.
Annual Meeting for Young Oncologists, November 2003, Albertslund, Denmark.
The 9th International Congress on Hyperthermic Oncology, April, 2004, St. Louis, MO, USA.
The 2nd International Conference on Vascular Targeting, May 2004, Miami, FL, USA.
The 23rd Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 2004, Amsterdam, The Netherlands.
The 1st Scandinavian Medical Educational Workshop, April 2005, Stockholm, Sweden.
The 1st European Society for Hyperthermic Oncology Educational Day, June, 2005, Graz, Austria.
The 24th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, October, 2006, Leipzig, Germany.
The 3rd European Society for Hyperthermic Oncology Educational Day, May, 2007, Prague, Czech Republic.
The 24th Annual Meeting of the European Society for Hyperthermic Oncology, May, 2007, Prague, Czech Republic.
The Association for Radiation Research Annual Meeting, April, 2008, Manchester, UK.
The 10th International Congress on Hyperthermic Oncology, April, 2008, Munich, Germany.
The 25th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September, 2008, Göteborg, Sweden.
The International Conference on Tumor hypoxia and malignant progression, October, 2008, Kiev, Ukraine.
The European Union 6th Framework BioCare Project Consensus Meeting, December, 2008, Brussels, Belgium.
The 4th International Conference on Translational Research and pre-clinical Strategies in Radiation Oncology, March, 2009, Geneva, Switzerland.
The 5th European Society for Hyperthermic Oncology Educational Day, June, 2009, Verona, Italy.
The 25th Annual Meeting of the European Society for Hyperthermic Oncology, June, 2009, Verona, Italy.
The 15th Annual Meeting of the German Society for Radiooncology, June, 2009, Bremen, Germany. ViVox workshop: Tools for cell therapy, November, 2009, Aarhus, Denmark.
The Association for Radiation Research Annual Meeting, June 2010, Oxford, UK.
The International Conference on Tumor and Host: novel aspects of old problem, September 2010, Kiev, Ukraine. Thermal Workshop on RF Hotspots, March, 2011, Zurich, Switzerland.
Radiation Oncology in Prostate Cancer Conference, April, 2011, Munich, Germany.
The 7th Biennial Conference of the Indian Association of Hyperthermic Oncology and Medicine, February 2012, Indore, India.
The 5th International Conference on Translational Research and Pre-Clinical Strategies in Radiation Oncology, March, 2012, Geneva, Switzerland.
The 29th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, May, 2012, Barcelona, Spain.
The Annual Meeting of the Radiation Research Society, October, 2012, Puerto Rico.
The 2nd International Conference on Tumor Microenvironment and Cellular Stress: Signalling, Metabolism, Imaging and Therapeutic Targets, September, 2013, Corfu, Greece.
The European Society for Hyperthermic Oncology School on Hyperthermia & Thermal Ablation in Cancer Therapy, February, 2014, Huntsham, UK.
The 6th International Conference on Translational Research in Radiation Oncology, February, 2014, Geneva, Switzerland.
The 29th Annual Meeting of the European Society for Hyperthermic Oncology, June, 2014, Torino, Italy.
The Annual Meeting of the Radiation Research Society, September, 2014, Las Vegas, USA.
Workshop on Translational Research in Ion Beam Cancer Therapy, October 2014, Aarhus, Denmark.
The Winter School for Therapeutic Ultrasound, March 8-13, 2015, Les Houches, France.
The 3rd European Society for Therapeutic Radiology & Oncology Forum, April 24-28 2015, Barcelona, Spain.
The 15th International Congress of Radiation Research, May 25-29, 2015, Kyoto, Japan.
The 30th Annual Meeting of the European Society for Hyperthermic Oncology, June 24-27, 2015, Zurich, Switzerland.
The Annual Meeting of the European Association for Nuclear Medicine, October 10-14, 2015, Hamburg, Germany.
The J.M. Brown Retirement Symposium, May 20-21, 2016, Palo Alto, California, USA.
The 4th International Conference on Tumor Microenvironment and Cellular Stress: Signalling, Metabolism, Imaging and Therapeutic Targets, June 5-10, 2016, Rhodes, Greece.
The Annual Meeting of the Radiation Research Society, October, 2016, Hawaii, USA.
The 31st Annual Meeting of the European Society for Hyperthermic Oncology, June 21-23, 2017, Athens, Greece.
The Winter School for Therapeutic Ultrasound, March 26-31, 2017, Les Houches, France.
National Meeting on Particle Therapy in Denmark, August 21-22, 2017, Aarhus, Denmark.

Andre videnskabelige aktiviteter

Member of the discussant panel for the Symposium on Clinical Implications for Moderate Hyperthermia at the 16th Annual Meeting of the North American Hyperthermia Society, May 1997, Providence, RI, USA.
Introducer for the Refresher Course "Tumour Microcirculation in Radiotherapy" given by Professor P.W. Vaupel at the 45th Annual Meeting of the Radiation Research Society, May 1997, Providence, RI, USA.
Abstract Reviewer for the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology, November 2001, San Fransisco, CA, USA.
Member of the Panel Discussion at the PTAC Workshop on MRI Methodology for the Pharmacodynamic Assessment of Antivasular and Antiangiogenic Agents, March 2002, London, England.
Member of the WHO Temperature Workshop, March 2002, Geneva, Switzerland.
Member of the Selection Committee for Best Oral Presentation at the Danish Society for Cancer Research Annual Meeting, May 2002, Vilvorde, Denmark.
Abstract Reviewer for the 45th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, October 2003, Salt Lake City, Utah, USA.
Member of the Antivasular therapy taxonomy and terminology expert panel meeting, December 2003, London, UK.
Abstract Reviewer for the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, October 2004, Atlanta, GA, USA.
Member of the International Atomic Energy Agency Technical Meeting Committee August, 2004, Budapest, Hungary.
Abstract Reviewer for the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, October 2005, Denver, CO, USA.
Abstract Reviewer for the Annual Meetings of the Danish Association for Cancer Research, 2006-2008, Vilvorde, Denmark.
Abstract Reviewer for Biology and Physiology section of the 10th International Congress on Hyperthermic Oncology, April, 2008, Munich, Germany.
Introducer of the Award lecture given by Prof. Hans Skovgaard-Poulsen at the Danish Association for Cancer Research Annual Meeting, April, 2008, Vilvorde, Denmark.
Member of the Selection Committee for Best Poster Presentation at the Danish Association for Cancer Research Annual Meeting, May 2008, Vilvorde, Denmark.
Member of the Selection Committee for Best Biology Poster Presentation at the International Congress of Hyperthermic Oncology, August 2012, Kyoto, Japan.
Member of the Selection Committee for the ESHO Student Awards presented at the 28th Annual Meeting of the European Society for Hyperthermic Oncology, June 2013, Munich, Germany.
Member of the Selection Committee for the ESHO Student Awards presented at the 29th Annual Meeting of the European Society for Hyperthermic Oncology, June 2014, Torino, Italy.
Abstract Reviewer for the 3rd Biology-Guided Adaptive Radiotherapy Symposium, June 2015, Aarhus, Denmark.
Member of the Selection Committee for the ESHO Student Awards presented at the 30th Annual Meeting of the European Society for Hyperthermic Oncology, June 2015, Zurich, Switzerland.
Member of the Selection Committee for Best Poster Presentation at the Danish Association for Cancer Research Annual Meeting, April 2016, Vilvorde, Denmark.
Chairman of the external Scientific Advisory Board for the Cancer Research UK Imaging Centre, January 2017, Sutton, Surrey, UK.

Videnskabelige mødeoplæg

Oplæg: 499 (med abstracts: 437; uden abstracts: 62)
Som forfatter: 241

Inviteret oplægsholder på afdelingsseminarer

M.R.C. Radiobiology Unit, Chilton, Oxon, England (December 1985).
Medical Biophysics Unit, B.C. Cancer Research Center, Vancouver, British Columbia, Canada (August 1986).
M.R.C. Clinical Oncology and Radiotherapeutics Unit, Cambridge, England (November 1987).
C.R.C. Gray Laboratory, Mount Vernon Hospital, Northwood, England (November 1987).
Radiotherapy Research Unit, Institute of Cancer Research, Sutton, England (November 1987).
Dept. Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA (April 1988).
Medical Biophysics Unit, B.C. Cancer Research Center, Vancouver, British Columbia, Canada (April 1988).
Dept. Radiology, Stanford University Medical Center, Stanford, CA, USA (April 1988).
Medical Biophysics Unit, B.C. Cancer Research Center, Vancouver, British Columbia, Canada (March 1989).
Joint Center for Radiation Therapy, Boston, MA, USA (June 1989).
C.R.C. Gray Laboratory, Mount Vernon Hospital, Northwood, England (December 1989).
C.R.C. Gray Laboratory, Mount Vernon Hospital, Northwood, England (December 1991).
Dept. Radiotherapy, University of Pisa, Pisa, Italy (January 1992).
Medical Biophysics Unit, B.C. Cancer Research Center, Vancouver, British Columbia, Canada (March 1992).
M.R.C. Clinical Oncology and Radiotherapeutics Unit, Cambridge, England (April 1993).
M.R.C. Radiobiology Unit, Chilton, Oxon, England (April 1993).
C.R.C. Gray Laboratory, Mount Vernon Hospital, Northwood, England (April 1993).

Dept. Ecogenetics, University of Lund, Lund, Sweden (January 1994).
Laboratory of Cellular Radiobiology, Gustave-Roussy Institute, Villejuif, France (February 1994).
Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA (April 1994).
Dept. Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA (April 1994).
Dept. Radiation Oncology, Duke University Medical Centre, Durham, NC, USA (November 1996).
Dept. Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA (November 1996).
Dept. Radiation Oncology, University of Florida, Gainesville, FL, USA (November 1996).
Dept. Radiation Therapy, University of Essen, Essen, Germany (June 1997).
Matrix Pharmaceutical Inc., Fremont, CA, USA (April 1998).
Dept. Radiology, Washington University School of Medicine, St. Louis, MO, USA (April 1998).
Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, England (August 1998).
Dept. Radiation Oncology, Lund University Hospital, Lund, Sweden (September 1998).
Dept. Pharmacology, University of Aarhus, Aarhus, Denmark (December 2000).
Dept. Pharmacology, University of Aarhus, Aarhus, Denmark (April 2003).
Dept. Biochemistry and Immunology, St. George's Hospital Medical School, London, England (February 2005).
Patterson Institute, University of Manchester, Manchester, UK (October 2005).
Dept. Radiation Oncology, University of Florida, Gainesville, FL, USA (August 2010).
Klinikum rechts der Isar, Technical University in Munich, Munich, Germany (August 2011).
The Institute of Cancer Research, Sutton, Surrey, UK (January 2017).
Dept. Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands (March 2017).

Involvering i videnskabelige tidsskrifter

TILKNYTTET REDAKTØR:

International Journal of Radiation Biology (2012-)

International Journal of Radiation Oncology Biology Physics (1995-2011)

Acta Oncologica (1992-)

MEDLEM AF REDAKTIONEL KOMITÉ:

Journal of Cancer Research and Therapeutics (2011-2016)

International Journal of Hyperthermia (1993-)

REDAKTIONELT GÆSTE MEDLEM:

Experimental Oncology (1996-2017)

GÆSTE REDAKTØR PÅ TIDSSKRIFTER:

Acta Oncologica (1995): 34: (3). Special issue dedicated to the International Workshop on the Tumor Microenvironment - its characterization, modification and clinical implications

International Journal of Hyperthermia (2008): 24: (1). Special issue on Cellular and vascular effects of hyperthermia

International Journal of Hyperthermia (2010) 26: (3). Special issue on Tumour perfusion and Associated physiology: characterisation and significance for hyperthermia (2010)

MANUSKRIFT ANMELDER:

Over 500 peer reviewed for 65 International Journals

Medlemskaber

Association for Radiation Research

Radiation Research Society

European Society for Hyperthermic Oncology

Society for Experimental Biology and Medicine

British Association for Cancer Research

European Society for Therapeutic Radiology and Oncology

Dansk Selskab for Cancer Forskning

International Society on Oxygen Transport to Tissue

American Association for Cancer Research

European Society for Radiation Biology

European Association for Cancer Research

American Society for Therapeutic Radiology and Oncology

Publikationer

Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers

Rykkelid, A. M., Sinha, P. M., Folefac, C. A., Horsman, M. R., Sørensen, B. S., Søland, T. M., Schreurs, O. J. F., Malinen, E. & Edin, N. F. J., 2024, I: Scientific Reports. 14, 1, 8 s., 11569.

***In Vitro* Characterization of the Bacteria-derived Hypoxia-selective Cytotoxin BE-43547**

Busk, M., Eggertsen, P. P., Overgaard, J., Horsman, M. R., Tørring, T., Jacobsen, K. M. & Poulsen, T. B., dec. 2023, I: Anticancer Research. 43, 12, s. 5319-5329 11 s.

Using immunotherapy to enhance the response of a C3H mammary carcinoma to proton radiation

Nielsen, S., Sitarz, M. K., Sinha, P. M., Folefac, C. A., Høyer, M., Sørensen, B. S. & Horsman, M. R., nov. 2023, I: Acta oncologica (Stockholm, Sweden). 62, 11, s. 1581-1586 6 s.

A patterns of care analysis of hyperthermia in combination with radio(chemo)therapy or chemotherapy in European clinical centers

Ademaj, A., Veltsista, P. D., Marder, D., Hälg, R. A., Puric, E., Brunner, T. B., Crezee, H., Gabrys, D., Franckena, M., Gani, C., Horsman, M. R., Krempien, R., Lindner, L. H., Maluta, S., Notter, M., Petzold, G., Abdel-Rahman, S., Richetti, A., Thomsen, A. R. & Tsoutsou, P. & 4 flere, Fietkau, R., Ott, O. J., Ghadjar, P. & Riesterer, O., maj 2023, I: Strahlentherapie und Onkologie. 199, 5, s. 436-444 9 s.

The effect of single bout and prolonged aerobic exercise on tumor hypoxia in mice

Elming, P. B., Busk, M., Wittenborn, T. R., Bussink, J., Horsman, M. R. & Lønbro, S., mar. 2023, I: Journal of Applied Physiology. 134, 3, s. 692-702 11 s.

Therapeutic Modification of Hypoxia

Horsman, M. R., Sørensen, B. S., Busk, M. & Siemann, D. W., nov. 2021, I: Clinical Oncology. 33, 11, s. e492-e509 18 s.

Refinement of an established procedure and its application for identification of hypoxia in prostate cancer xenografts

Elming, P. B., Wittenborn, T. R., Busk, M., Sørensen, B. S., Thomsen, M. B. H., Strandgaard, T., Dyrskjøt, L., Nielsen, S. & Horsman, M. R., jun. 2021, I: Cancers. 13, 11, 2602.

Does the combination of hyperthermia with low LET (linear energy transfer) radiation induce anti-tumor effects equivalent to those seen with high LET radiation alone?

Elming, P. B., Sørensen, B. S., Spejlborg, H., Overgaard, J. & Horsman, M. R., 2021, I: International Journal of Hyperthermia. 38, 1, s. 105-110 6 s.

In vitro hypoxia responsiveness of [¹⁸F] FDG and [¹⁸F] FAZA retention: influence of shaking versus stagnant conditions, glass versus polystyrene substrata and cell number down-scaling

Busk, M., Horsman, M. R., Overgaard, J. & Jakobsen, S., 1 dec. 2020, I: EJNMMI Radiopharmacy and Chemistry. 5, 1, 14.

Proton scanning and X-ray beam irradiation induce distinct regulation of inflammatory cytokines in a preclinical mouse model

Nielsen, S., Bassler, N., Grzanka, L., Swakon, J., Olko, P., Horsman, M. R. & Sørensen, B. S., okt. 2020, I: International Journal of Radiation Biology. 96, 10, s. 1238-1244 7 s.

Tumors resistant to checkpoint inhibitors can become sensitive after treatment with vascular disrupting agents

Horsman, M. R., Wittenborn, T. R., Nielsen, P. S. & Elming, P. B., jul. 2020, I: International Journal of Molecular Sciences. 21, 13, s. 1-14 14 s., 4778.

Molecular and biological rationale of hyperthermia as radio- and chemosensitizer

Oei, A. L., Kok, H. P., Oei, S. B., Horsman, M. R., Stalpers, L. J. A., Franken, N. A. P. & Crezee, J., 2020, I: Advanced Drug Delivery Reviews. 163-164, s. 84-97 14 s.

Dual-tracer PET of viable tumor volume and hypoxia for identification of necrosis-containing radio-resistant Sub-volumes

Busk, M., Horsman, M. R., Overgaard, J. & Jakobsen, S., 2019, I: Acta Oncologica. 58, 10, s. 1476-1482 7 s.

Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running

Lønbro, S., Wiggins, J. M., Wittenborn, T., Elming, P. B., Rice, L., Pampo, C., Lee, J. A., Siemann, D. W. & Horsman, M. R., 2019, I: PLOS ONE. 14, 5, 15 s., e0215584.

APD-Containing Cyclolipodepsipeptides Target Mitochondrial Function in Hypoxic Cancer Cells

Jacobsen, K. M., Villadsen, N. L., Tørring, T., Nielsen, C. B., Salomón, T., Nielsen, M. M., Tsakos, M., Sibbersen, C., Scavenius, C., Nielsen, R., Christensen, E. I., Guerra, P. F., Bross, P., Pedersen, J. S., Enghild, J. J., Johannsen, M.,

Frøkiær, J., Overgaard, J., Horsman, M. R. & Busk, M. & 1 flere, Poulsen, T. B., nov. 2018, I: Cell Chemical Biology. 25, 11, s. 1337-1349.e12 13 s.

Enhancing the radiation response of tumors but not early or late responding normal tissues using a vascular disrupting agent

Horsman, M. R., nov. 2017, I: Acta Oncologica. 56, 11, s. 1634-1638 5 s.

Hypoxia positron emission tomography imaging: combining information on perfusion and tracer retention to improve hypoxia specificity

Busk, M., Munk, O. L., Jakobsen, S. S. & Horsman, M. R., nov. 2017, I: Acta Oncologica. 56, 11, s. 1583-1590 8 s.

Relative biological effectiveness (RBE) and distal edge effects of proton radiation on early damage in vivo

Sørensen, B. S., Bassler, N., Nielsen, S., Horsman, M. R., Grzanka, L., Spejlborg, H., Swakoń, J., Olko, P. & Overgaard, J., nov. 2017, I: Acta Oncologica. 56, 11, s. 1387-1391 5 s.

Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer

Siemann, D. W., Chaplin, D. J. & Horsman, M. R., 14 sep. 2017, I: Cancer Investigation. 35, 8, s. 519-534 16 s.

Results from (11)C-metformin-PET scans, tissue analysis and cellular drug-sensitivity assays questions the view that biguanides affects tumor respiration directly

Iversen, A. B., Horsman, M. R., Jakobsen, S., Jensen, J. B., Garm, C., Jessen, N., Breining, P., Frøkiær, J. & Busk, M., 25 aug. 2017, I: Scientific Reports. 7, 1, s. 9436 13 s., 9436.

FDG-PET reproducibility in tumor-bearing mice: comparing a traditional SUV approach with a tumor-to-brain tissue ratio approach

Busk, M., Munk, O. L., Jakobsen, S., Frøkiær, J., Overgaard, J. & Horsman, M. R., maj 2017, I: Acta Oncologica. 56, 5, s. 706-712 7 s.

Targeting therapy-resistant cancer stem cells by hyperthermia

Oei, A. L., Vriend, L. E. M., Krawczyk, P. M., Horsman, M. R., Franken, N. A. P. & Crezee, J., 2017, I: International Journal of Hyperthermia. 33, 4, s. 419-427 12 s.

The potential of hyperpolarized (13)C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agents

Iversen, A. B., Busk, M., Bertelsen, L. B., Laustsen, C., Munk, O. L., Nielsen, T., Wittenborn, T. R., Bussink, J., Lok, J., Stødkilde-Jørgensen, H. & Horsman, M. R., 2017, I: Acta Oncologica. 56, 11, s. 1-8 8 s.

Simulation of heterogeneous molecular delivery in tumours using μ CT reconstructions and MRI validation

Wittenborn, T. R., Nielsen, T., Thomsen, J. S., Horsman, M. R. & Nygaard, J. V., 26 aug. 2016, I: Microvascular Research. 108, s. 69-74 6 s.

The impact of hypoxia and its modification of the outcome of radiotherapy

Horsman, M. R. & Overgaard, J., 16 aug. 2016, I: Journal of Radiation Research. 57, 1, s. 90-98 9 s.

Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L

Parker, E. N., Song, J., Kishore Kumar, G. D., Odutola, S. O., Chavarria, G. E., Charlton-Sevcik, A. K., Strecker, T. E., Barnes, A. L., Sudhan, D. R., Wittenborn, T. R., Siemann, D. W., Horsman, M. R., Chaplin, D. J., Trawick, M. L. & Pinney, K. G., 1 nov. 2015, I: Bioorganic & Medicinal Chemistry. 23, 21, s. 6974-6992 19 s.

Relative biological effectiveness of carbon ions for tumor control, acute skin damage and late radiation-induced fibrosis in a mouse model

Sørensen, B. S., Horsman, M. R., Alsner, J., Overgaard, J., Durante, M., Scholz, M., Friedrich, T. & Bassler, N., 21 okt. 2015, I: Acta Oncologica. 54, 9, s. 1623-1630 8 s.

Photoelectron Spectra and Electronic Structures of the Radiosensitizer Nimorazole and Related Compounds

Feketeová, L., Plekan, O., Goonewardane, M., Ahmed, M., Albright, A. L., White, J., O'Hair, R. A. J., Horsman, M. R., Wang, F. & Prince, K. C., 1 okt. 2015, I: *Journal of Physical Chemistry Part A: Molecules, Spectroscopy, Kinetics, Environment and General Theory*. 119, 39, s. 9986-95 10 s.

Hyperpolarized magnetic resonance spectroscopy for assessing tumor hypoxia

Iversen, A. B., Ringgaard, S., Laustsen, C., Stødtkilde-Jørgensen, H., Bentzen, L., Busk, M. & Horsman, M. R., 4 sep. 2015, I: *Acta Oncologica*. s. 1393-1398 6 s.

Modulation of the tumor vasculature and oxygenation to improve therapy

Siemann, D. W. & Horsman, M. R., sep. 2015, I: *Pharmacology & Therapeutics*. 153, 9, s. 107-24 18 s.

The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types

Sørensen, B. S., Knudsen, A. B., Wittrup, C. F., Nielsen, S., Aggerholm-Pedersen, N., Busk, M., Horsman, M., Høyer, M., Bouchelouche, P. N., Overgaard, J. & Alsner, J., sep. 2015, I: *Radiotherapy & Oncology*. 116, 3, s. 346-51 6 s.

A tissue-engineered therapeutic device inhibits tumor growth in vitro and in vivo

Sun, M., Wang, M., Chen, M., Dagnaes-Hansen, F., Le, D. Q. S., Baatrup, A., Horsman, M. R., Kjems, J. & Bünger, C., maj 2015, I: *Acta Biomaterialia*. 18, s. 21-29 9 s.

Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation

Horsman, M. R., maj 2015, I: *International Journal of Hyperthermia*. 31, 5, s. 453-9 7 s.

Uniform Combretastatin-induced Effect on Monocytes and Neutrophils in Peripheral Blood but Not in Tumors

Bohn, A. B., Brems-Eskildsen, A. S., Møller, B. K. & Horsman, M. R., maj 2015, I: *Anticancer Research*. 35, 5, s. 2559-64 6 s.

Relative biological effectiveness of carbon ions for tumor control, acute skin damage and late radiation-induced fibrosis in a mouse model

Sørensen, B. S., Horsman, M. R., Alsner, J., Overgaard, J., Durante, M., Scholz, M., Friedrich, T. & Bassler, N., 2015, I: *Acta Oncologica*. 54, 9, s. 1623-1630 8 s.

Simultaneous Hypoxia and Low Extracellular pH Suppress Overall Metabolic Rate and Protein Synthesis In Vitro

Sørensen, B. S., Busk, M., Overgaard, J., Horsman, M. R. & Alsner, J., 2015, I: *PLOS ONE*. 10, 8, 14 s., e0134955.

Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy

Wittenborn, T. R. & Horsman, M. R., 2015, I: *Acta Oncologica*. 54, 9, s. 1385-92 8 s.

Effect of radiation on cell proliferation and tumor hypoxia in HPV-positive head and neck cancer in vivo models

Sørensen, B. S., Busk, M., Horsman, M. R., Alsner, J., Overgaard, J., Kyle, A. H. & Minchinton, A. I., nov. 2014, I: *Anticancer Research*. 34, 11, s. 6297-304 8 s.

In vivo bio-distribution and homing of endothelial outgrowth cells in a tumour model

Bertelsen, L. B., Hagensen, M., Busk, M., Zhang, R., Knudsen, A. S., Nielsen, N., Falborg, L., Møller, B. K., Horsman, M. R. & Stødtkilde-Jørgensen, H., 1 aug. 2014, I: *Nuclear Medicine and Biology*. s. 848-855 8 s.

Formation of radical anions of radiosensitizers and related model compounds via electrospray ionization

Feketeová, L., Albright, A. L., Sørensen, B. S., Horsman, M. R., White, J., O'Hair, R. A. J. & Bassler, N., 15 maj 2014, I: *International Journal of Mass Spectrometry*. 365-366, s. 56-63 8 s.

Accumulation of nano-sized particles in a murine model of angiogenesis

Wittenborn, T. R., Larsen, E. K. U., Nielsen, T., Rydtoft, L. M., Hansen, L., Nygaard, J. V., Vorup-Jensen, T., Kjems, J., Horsman, M. R. & Nielsen, N. C., 10 jan. 2014, I: *Biochemical and Biophysical Research Communications*. 443, 2, s. 470-6 7 s.

A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models

Bohn, A. B., Wittenborn, T., Brems-Eskildsen, A. S., Laurberg, T., Bertelsen, L. B., Nielsen, T., Stødkilde-Jørgensen, H., Møller, B. K. & Horsman, M. R., 2014, I: PLOS ONE. 9, 10, s. e1110091

Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model

Bertelsen, L. B., Bohn, A. B., Shen, Y. Y., Falborg, L., Stødkilde-Jørgensen, H. & Horsman, M. R., 2014, I: B M C Cancer. 14, s. 903 9 s.

Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy

Iversen, A. B., Busk, M. & Horsman, M. R., okt. 2013, I: Acta Oncologica. 52, 7, s. 1320-6 7 s.

Relevance of hypoxia in radiation oncology: pathophysiology, tumor biology and implications for treatment

Busk, M. & Horsman, M. R., sep. 2013, I: Quarterly Journal of Nuclear Medicine and Molecular Imaging. 57, 3, s. 219-234 16 s.

Ultra-high field (1)H magnetic resonance imaging approaches for acute hypoxia

Nielsen, T., Nielsen, N. C., Holm, T. H., Ostergaard, L., Horsman, M. R. & Busk, M., 30 aug. 2013, I: Acta Oncologica. 52, 7, s. 1287-1292

Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells

Sørensen, B. S., Busk, M., Olthof, N., Speel, E.-J., Horsman, M. R., Alsner, J. & Overgaard, J., 13 aug. 2013, I: Radiotherapy & Oncology. 108, 3, s. 500-505 6 s.

The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis

Østergaard, L., Tietze, A., Nielsen, T., Drasbek, K. R., Mouridsen, K., Jespersen, S. N. & Horsman, M. R., 13 jun. 2013, I: Cancer Research. 73, 18, s. 5618-5624 7 s.

Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo

Horsman, M. R., Christensen, K. L. & Overgaard, J., apr. 2013, I: International Journal of Hyperthermia. 5, 2, s. 123-36 14 s.

Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model

Nawroth, I., Alsner, J., Deleuran, B. W., Dagnæs-Hansen, F., Yang, C., Horsman, M. R., Overgaard, J., Howard, K., Kjems, J. & Gao, S., 1 jan. 2013, I: Acta Oncologica. 52, 8, s. 1730-1738 9 s.

PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice

Busk, M., Mortensen, L. S., Nordsmark, M., Overgaard, J., Jakobsen, S., Hansen, K. V., Theil, J., Kallehauge, J., D'Andrea, F. P., Steiniche, T. & Horsman, M. R., jan. 2013, I: European Journal of Nuclear Medicine and Molecular Imaging. 40, 2, s. 186-97 12 s.

PET imaging of tumor hypoxia using ¹⁸F-labeled pimonidazole

Busk, M., Jakobsen, S., Horsman, M. R., Mortensen, L. S., Iversen, A. B., Overgaard, J., Nordsmark, M., Ji, X., Lee, D. Y. & Raleigh, J. R., 2013, I: Acta Oncologica. 52, 7, s. 1300-1307 8 s.

Tumour microenvironment and radiation response in sarcomas originating from tumorigenic human mesenchymal stem cells

D'Andrea, F. P., Safwat, A. A., Burns, J. S., Kassem, M., Horsman, M. R. & Overgaard, J., jun. 2012, I: International Journal of Radiation Biology. 88, 6, s. 457-465 9 s.

Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging

Nielsen, T., Bentzen, L., Pedersen, M. N., Tramm, T., Rijken, P. F. J. W., Bussink, J., Horsman, M. R. & Østergaard, L., 2012, I: *Clinical Cancer Research*. 18, 23, s. 6469-77 9 s.

Imaging hypoxia to improve radiotherapy outcome

Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M. & Overgaard, J., 2012, I: *Nature Reviews. Clinical Oncology*. 9, 12, s. 674-87 14 s.

Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L

Chavarria, G. E., Horsman, M. R., Arispe, W. M., Kumar, G. D. K., Chen, S.-E., Strecker, T. E., Parker, E. N., Chaplin, D. J., Pinney, K. G. & Trawick, M. L., 2012, I: *European Journal of Medicinal Chemistry*. 58, s. 568-72 5 s.

Treatment with the vascular disrupting agent Combretastatin is associated with impaired AQP2 trafficking and increased urine output

Bohn, A. B., Norregaard, R., Stødkilde-Jørgensen, L., Wang, Y., Bertelsen, L. B., Fenton, R. A., Matchkov, V. V., Bouzinova, E. V., Horsman, M. R., Frokiaer, J. & Stødkilde-Jørgensen, H., 2012, I: *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology*. s. R186-R198 13 s.

Tumourigenicity and radiation resistance of mesenchymal stem cells

D'Andrea, F. P., Horsman, M. R., Kassem, M., Overgaard, J. & Safwat, A. A., 2012, I: *Acta Oncologica*. 51, 5, s. 669-679 11 s.

Ultra-High-Field DCE-MRI of Angiogenesis in a Novel Angiogenesis Mouse Model

Wittenborn, T., Nielsen, T., Nygaard, J. V., Larsen, E. K. U., Thim, T., Rydtoft, L. M., Vorup-Jensen, T., Kjems, J., Nielsen, N. C., Horsman, M. R. & Falk, E., 2012, I: *Journal of Magnetic Resonance Imaging*. 35, 3, s. 703-710 7 s.

Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation

Bertelsen, L. B., Shen, Y. Y., Nielsen, T., Stødkilde-Jørgensen, H., Lloyd, G. K., Siemann, D. W. & Horsman, M. R., nov. 2011, I: *International Journal of Radiation Biology*. 87, 11, s. 1126-1134 9 s.

Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance

D'Andrea, F. P., Safwat, A. A., Kassem, M., Gautier, L., Overgaard, J. & Horsman, M. R., jun. 2011, I: *Radiotherapy & Oncology*. 99, 3, s. 373-378 6 s.

In vivo Identification and Specificity assessment of mRNA markers of hypoxia in human and mouse tumors

Busk, M., Toustrup, K., Soerensen, B. S., Alsner, J., Horsman, M. R., Jakobsen, S. & Overgaard, J., 9 feb. 2011, I: *B M C Cancer*. 11, 1, s. 63

Assessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study

Mortensen, L. S., Busk, M., Nordmark, M., Jakobsen, S., Theil, J., Overgaard, J. & Horsman, M. R., 2011, I: *Radiotherapy & Oncology*. 99, 3, s. 418-23 6 s.

Combretastatin-induced hypertension and the consequences for its combination with other therapies

Busk, M., Bohn, A. B., Skals, M., Wang, T. & Horsman, M. R., 2011, I: *Vascular Pharmacology*. 54, 1-2, s. 13-17 5 s.

Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment

Busk, M., Walenta, S., Mueller-Klieser, W., Steiniche, T., Jakobsen, S., Horsman, M. R. & Overgaard, J., 2011, I: *Radiotherapy & Oncology*. s. 404-11 8 s.

Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival

Offersen, B. V., Knap, M. M., Horsman, M. R., Verheijen, J., Hanemaaijer, R. & Overgaard, J., 1 nov. 2010, I: *Acta Oncologica*. 49, 8, s. 1283-7 5 s.

Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro

Sørensen, B. S., Toustrup, K., Horsman, M. R., Overgaard, J. & Alsner, J., okt. 2010, I: *Acta Oncologica*. 49, 7, s. 895-905 11 s.

Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan

Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M.-T. & Lassen, U., 1 aug. 2010, I: *Acta Pathologica Microbiologica et Immunologica Scandinavica*. 118, 8, s. 585-94 10 s.

Tumour perfusion and associated physiology: characterization and significance for hyperthermia

Vaupel, P. & Horsman, M. R., 1 jan. 2010, I: *International Journal of Hyperthermia*. 26, 3, s. 209-10 2 s.

Assessing hypoxia in animal tumor models based on pharmacokinetic analysis of dynamic FAZA PET

Busk, M., Munk, O. L., Jakobsen, S., Wang, T., Skals, M., Steiniche, T., Horsman, M. R. & Overgaard, J., 2010, I: *Acta Oncologica*. 49, 7, s. 922-33 11 s.

Biodistribution of ^{99m}Tc-HYNIC-lactadherin in mice - a potential tracer for visualizing apoptosis in vivo

Falborg, L., Waehrens, L. N., Alsner, J., Bluhme, H., Frøkiaer, J., Heegaard, C. W., Horsman, M. R., Rasmussen, J. T. & Rehling, M., 2010, I: *Scandinavian Journal of Clinical & Laboratory Investigation*. 70, 3, s. 209-16 7 s.

Imaging tumour physiology and vasculature to predict and assess response to heat

Hokland, S., Nielsen, T., Busk, M. & Horsman, M. R., 2010, I: *International Journal of Hyperthermia*. 26, 3, s. 264-72 8 s.

Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates

Nielsen, T., Murata, R., Maxwell, R. J., Stødkilde-Jørgensen, H., Østergaard, L., Ley, C. D., Kristjansen, P. E. G. & Horsman, M. R., 2010, I: *Acta Oncologica*. 49, 7, s. 906-13 7 s.

NPI-2358 Rapidly Inhibit the Blood Flow in Tumour Treatment by Analyzing Dynamic Contrast Enhanced Magnetic Resonance Imaging Parameters

Shen, Y. Y., Liu, C.-X., Bertelsen, L. B., Nielsen, T., Horsman, M. R. & Stødkilde-Jørgensen, H., 2010, I: *China Journal of Cancer Prevention and Treatment*. 7, s. 488-490 3 s.

Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?

Busk, M., Horsman, M. R., Jakobsen, S., Hansen, K. V., Bussink, J., van der Kogel, A. & Overgaard, J., sep. 2009, I: *Radiotherapy & Oncology*. 92, 3, s. 429-436 7 s.

A Novel in Vivo Angiogenesis Mouse Model

Wittenborn, T., Nygaard, J. V., Horsman, M. R., Vorup-Jensen, T., Kjems, J., Thim, T., Nielsen, T., Larsen, E. K. U. & Falk, E., 2009, I: *Arteriosclerosis, Thrombosis, and Vascular Biology*. 7

Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics

Sørensen, B. S., Horsman, M. R., Vorum, H., Honoré, B., Overgaard, J. & Alsner, J., 2009, I: *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 92, 3, s. 443-9 6 s.

Size-Dependent Accumulation of PEGylated Silane-Coated Magnetic Iron Oxide Nanoparticles in Murine Tumors

Larsen, E. K. U., Nielsen, T., Wittenborn, T., Birkedal, H., Vorup-Jensen, T., Jakobsen, M. H., Østergaard, L., Horsman, M. R., Besenbacher, F., Howard, K. A. & Kjems, J., 2009, I: *A C S Nano*. 3, 7, s. 1947-51 5 s.

Vascular targeted therapies in oncology

Siemann, D. W. & Horsman, M. R., 2009, I: *Cell and Tissue Research*. 335, 1, s. 241-8 7 s.

Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage

Busk, M., Horsman, M. R., Jakobsen, S., Bussink, J., van der Kogel, A. & Overgaard, J., dec. 2008, I: European Journal of Nuclear Medicine and Molecular Imaging. 35, 12, s. 2294-303 10 s.

Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia

Busk, M., Horsman, M. R., Kristjansen, P. E. G., van der Kogel, A. J., Bussink, J. & Overgaard, J., 15 jun. 2008, I: International Journal of Cancer. 122, 12, s. 2726-34 9 s.

Imaging Hypoxia in Xenografted and Murine Tumors with ¹⁸F-Fluoroazomycin Arabinoside: A Comparative Study Involving microPET, Autoradiography, pO₂-Polarography, and Fluorescence Microscopy

Busk, M., Horsman, M. R., Jakobsen, S., Keiding, S., van der Kogel, A. J., Bussink, J. & Overgaard, J., 15 mar. 2008, I: International Journal of Radiation Oncology, Biology, Physics. 70, 4, s. 1202-12 11 s.

Angiogenesis and vascular targeting: Relevance for hyperthermia.

Horsman, M. R., 2008, I: International Journal of Hyperthermia. 24, 1, s. 57-65 8 s.

Cellular and vascular effects of hyperthermia

Milani, V. & Horsman, M. R., 2008, I: International Journal of Hyperthermia. 24, 1, s. 1-2 1 s.

Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole

Murata, R., Tsujitani, M. & Horsman, M. R., 2008, I: Radiotherapy & Oncology. 87, 3, s. 331-8 7 s.

Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients

Nielsen, T., Murata, R., Maxwell, R. J., Stødkilde-Jørgensen, H., Østergaard, L. & Horsman, M. R., 2008, I: International Journal of Radiation Oncology, Biology, Physics. 70, 3, s. 859-66 8 s.

Resolution in PET hypoxia imaging: voxel size matters

Busk, M., Horsman, M. R. & Overgaard, J., 2008, I: Acta Oncologica. 47, 7, s. 1201-10 10 s.

Segmentation of dynamic contrast enhanced magnetic resonance imaging data

Nielsen, T., Mouridsen, K., Maxwell, R. J., Stødkilde-Jørgensen, H., Østergaard, L. & Horsman, M. R., 2008, I: Acta Oncologica. 47, 7, s. 1265-70 5 s.

The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.

Chen, G., Horsman, M. R., Pedersen, M., Pang, Q. & Stødkilde-Jørgensen, H., 2008, I: Acta Oncologica. 47, 6, s. 1071-6 5 s.

The impact of hypoxia on the activity of lactate dehydrogenase in two different pre-clinical tumour models

Lukacova, S., Sørensen, B., Alsner, J., Overgaard, J. & Horsman, M., 2008, I: Acta Oncologica. 47, 5, s. 941-47 7 s.

Hyperthermia: a potent enhancer of radiotherapy

Horsman, M. R. & Overgaard, J., aug. 2007, I: Clinical Oncology. 19, 6, s. 418-426 9 s.

Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients

Nordmark, M., Eriksen, J. G., Gebiski, V., Alsner, J., Horsman, M. R. & Overgaard, J., jun. 2007, I: Radiotherapy & Oncology. 83, 3, s. 389-397 9 s.

Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH

Sørensen, B. S., Alsner, J., Overgaard, J. & Horsman, M. R., jun. 2007, I: Radiotherapy & Oncology. 83, 3, s. 362-366

Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure

Ley, C. D., Horsman, M. R. & Kristjansen, P. E. G., 2007, I: *NeoPlasia*. 9, 2, s. 108-112

The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitisation

Hokland, S. & Horsman, M. R., 2007, I: *International Journal of Hyperthermia*. 23, 7, s. 599-606

Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models

Lukáčová, S., Overgaard, J., Alsner, J. & Horsman, M. R., aug. 2006, I: *Radiotherapy & Oncology*. 80, 2, s. 165-171 7 s.

Current development status of small-molecule vascular disrupting agents

Chaplin, D. J., Horsman, M. R. & Siemann, D. W., 2006, I: *Current Opinion in Investigational Drugs*. 7, 6, s. 522-8 7 s.

Hyperthermia is effective in improving clinical radiotherapy results: in response to Drs. Van der Zee and van Rhoon

Horsman, M. R., 2006, I: *International Journal of Radiation Oncology, Biology, Physics*. 66, s. 634

Is expression of the epidermal growth factor receptor related to hypoxia in squamous cell carcinomas of the head and neck - an evaluation of the DAHANCA 5 study

Eriksen, J. G., Nordmark, M., Alsner, J., Horsman, M. R., Steinicke, T. & Overgaard, J., 2006, *Radiother Oncol.* 78 (Suppl.1) udg. s. S38 1 s.

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies

Horsman, M. R. & Siemann, D. W., 2006, I: *Cancer Res.* 66, s. 11520-11539

Preclinical studies in murine tumours to elucidate the role of serum osteopontin as an endogenous marker of hypoxia

Lukáčová, S., Khalil, A. A., Overgaard, J., Alsner, J. & Horsman, M. R., 2006, *Radiother. Oncol.* 78 (Suppl.1) udg. s. S31 1 s.

Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response

Horsman, M. R., Nielsen, T., Østergaard, L. & Overgaard, J., 2006, I: *Acta Oncologica*. 45, 7, s. 876-80 5 s.

The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS

Breidahl, T., Nielsen, F. U., Stødkilde-Jørgensen, H., Maxwell, R. & Horsman, M. R., 2006, I: *Acta. Oncol.* 45, 3, s. 306-316 10 s.

Tissue physiology and the response to heat

Horsman, M. R., 2006, I: *Int. J. Hyperthermia*. 22, s. 197-203

Tumor radiosensitizers - current status of development of various approaches: Report of an International Atomic Energy Agency meeting

Horsman, M. R., Bohm, L., Margison, G. P., Milas, L., Rosier, J.-F., Safrany, G., Selzer, E., Verheij, M. & Hendry, J. H., 2006, I: *International Journal of Radiation Oncology, Biology, Physics*. 64, s. 551-561

Tumour hypoxia - a characteristic feature with a complex molecular background

Eriksen, J. G. & Horsman, M. R., 2006, I: *Radiother. Oncol.* 81, s. 119-121

Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum

Lukáčová, S., Khalil, A. A., Overgaard, J., Alsner, J. & Horsman, M. R., dec. 2005, I: *International Journal of Radiation Biology*. 81, 12, s. 937-944 8 s.

Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial

Overgaard, J., Eriksen, J. G., Nordmark, M., Alsner, J. & Horsman, M. R., okt. 2005, I: *Lancet Oncology*. 6, 10, s. 757-764 8 s.

Influence of oxygen concentration and pH on expression of hypoxia induced genes

Sørensen, B. S., Hao, J., Overgaard, J., Vorum, H., Honore, B., Alsner, J. & Horsman, M. R., aug. 2005, I: *Radiotherapy & Oncology*. 76, 2, s. 187-193 7 s.

Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor

Bentzen, L., Vestergaard-Poulsen, P., Nielsen, T., Overgaard, J., Bjørnerud, A., Briley-Saebø, K., Horsman, M. R. & Østergaard, L., 15 mar. 2005, I: *International Journal of Radiation Oncology, Biology, Physics*. 61, 4, s. 1208-15 8 s.

Differentiation and definition of vascular-targeted therapies

Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Horsman, M. R., Marmé, D. & LoRusso, P. M., 2005, I: *Clinical Cancer Research*. 11, 2 Pt 1, s. 416-420

Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode pO₂ measurements in murine tumors

Sørensen, M., Horsman, M. R., Cumming, P., Munk, O. L. & Keiding, S., 2005, I: *International Journal of Radiation Oncology, Biology, Physics*. 62, 3, s. 854-861

Evaluation of anti-vascular therapy with texture analysis

Chen, G., Jespersen, S., Pedersen, M., Pang, Q., Horsman, M. R. & Stødkilde-Jørgensen, H., 2005, I: *Anticancer Research*. 25, 5, s. 3399-3405 7 s.

Experience with mouse hepatitis virus sanitation in three transplantable murine tumour lines

Dagnæs-Hansen, F. & Horsman, M. R., 2005, I: *Lab Anim*. 39, 4, s. 394-399

Influence of oxygen concentration and pH on expression of hypoxia induced genes

Sørensen, B. S., Hao, J., Overgaard, J., Alsner, J. & Horsman, M. R., 2005, *Proceedings of the 9th International Wolfsberg Meeting on Molecular Radiation Biology / Oncology*. 6 udg. s. 75 1 s.

Intravenous administration of Gd-DTPA prior to DWI does not affect the apparent diffusion constant

Chen, G., Jespersen, S., Pedersen, M., Qi, P., Horsman, M. R. & Stødkilde-Jørgensen, H., 2005, I: *Magn Reson Imaging*. 23, 5, s. 685-689 5 s.

The assessment of antiangiogenic and antivasular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

Leach, M. O., Brindle, K. M., Evelhoch, J. L., Griffiths, J. R., Horsman, M. R., Jackson, A., Jayson, C. G., Judson, I. R., Knopp, M. V., Maxwell, R. J., McIntyre, D., Padhani, A. R., Price, P., Rathbone, R., Rustin, G. J., Tofts, P. S., Tozer, G. M., Vennart, W., Waterton, J. C. & Williams, S. R. & 1 flere, Workman, P., 2005, I: *Br. J. Cancer*. 92, 9, s. 1599-1610

Vascular-targeting therapies for treatment of malignant disease

Siemann, D. W., Chaplin, D. J. & Horsman, M. R., 15 jun. 2004, I: *Cancer*. 100, 12, s. 2491-2499 9 s.

Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

Murata, R. & Horsman, M. R., jun. 2004, I: *International Journal of Hyperthermia*. 20, 4, s. 393-404 12 s.

Targeting the tumor vasculature: a strategy to improve radiation therapy

Siemann, D. W. & Horsman, M. R., apr. 2004, I: *Expert Review of Anticancer Therapy*. 4, 2, s. 321-327 7 s.

Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen

Horsman, M. R. & Overgaard, J., mar. 2004, I: *Radiotherapy & Oncology*. 70, 3, s. 301-309 9 s.

Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma

Grönroos, T., Bentzen, L. N., Marjamäki, P., Murata, R., Horsman, M. R., Keiding, S., Eskola, O., Haaparanta, M., Minn, H. & Solin, O., 2004, I: *European Journal of Nuclear Medicine and Molecular Imaging*. 31, s. 513-520 8 s.

Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response

Horsman, M. R. & Murata, R., 15 nov. 2003, I: *International Journal of Radiation Oncology, Biology, Physics*. 57, 4, s. 1047-1055 9 s.

Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis

Offersen, B. V., Knap, M., Marcussen, N., Horsman, M. R., Hamilton-Dutoit, S. J. & Overgaard, J., 2 dec. 2002, I: *British Journal of Cancer*. 87, 12, s. 1422-1430 9 s.

Combination of vascular targeting agents with thermal and radiation therapy

Horsman, M. R. & Murata, R., 1 dec. 2002, I: *International Journal of Radiation Oncology, Biology, Physics*. 54, 5, s. 1518-1523 6 s.

Enhancement of radiation therapy by vascular targeting agents

Siemann, D. W. & Horsman, M. R., nov. 2002, I: *Current Opinion in Investigational Drugs*. 3, 11, s. 1660-1665 6 s.

Acute effects of vascular modifying agents in solid tumors assessed by non-invasive laser Doppler flowmetry (LDF) and near infrared spectroscopy (NIRS)

Kragh, M., Quistorff, B., Horsman, M. R. & Kristjansen, P. E. G., jun. 2002, I: *NeoPlasia*. 4, 3, s. 263-267 5 s.

Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO₂ electrode measurements. Influence of tumour volumes and carbogen breathing

Bentzen, L. N., Keiding, S., Horsman, M. R., Grönroos, T., Hansen, S. B. & Overgaard, J., 2002, I: *Acta Oncologica*. 41, 3, s. 304-312 9 s.

Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy

Murata, R., Overgaard, J. & Horsman, M. R., 15 nov. 2001, I: *International Journal of Radiation Oncology, Biology, Physics*. 51, 4, s. 1018-1024 7 s.

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

Murata, R., Siemann, D. W., Overgaard, J. & Horsman, M. R., nov. 2001, I: *Radiation Research*. 156, 5 pt 1, s. 503-509 7 s.

Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

Murata, R., Overgaard, J. & Horsman, M. R., nov. 2001, I: *International Journal of Hyperthermia*. 17, 6, s. 508-519 12 s.

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

Murata, R., Siemann, D. W., Overgaard, J. & Horsman, M. R., aug. 2001, I: *Radiotherapy & Oncology*. 60, 2, s. 155-161 7 s.

Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo nuclear magnetic resonance spectroscopy

Nielsen, F. U., Daugård, P., Bentzen, L. N., Overgaard, J., Stødkilde-Jørgensen, H., Horsman, M. R. & Maxwell, R. J., 1 jul. 2001, I: *Cancer Research*. 61, 13, s. 5318-25 8 s.

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues

Murata, R., Overgaard, J. & Horsman, M. R., feb. 2001, I: International Journal of Radiation Biology. 77, 2, s. 195-204 10 s.

A future for hyperthermia in cancer treatment?

Nielsen, O. S., Horsman, M. R. & Overgaard, J., 2001, I: European Journal of Cancer. 37, 13, s. 1587-9 3 s.

Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo Nuclear Magnetic Resonance spectroscopy

Nielsen, F. U., Christensen, P. D., Overgaard, J., Stødkilde-Jørgensen, H., Horsman, M. R. & Maxwell, R. J., 2001, I: Cancer Res.. 61, 13, s. 5318-5325 8 s.

Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation

Horsman, M. R., Murata, R. & Overgaard, J., 2001, I: Acta Oncologica. 40, 4, s. 497-503 7 s.

Cadralazine: A less toxic but equally effective analogue of hydralazine in vivo

Horsman, M. R., Chaplin, D. J., Christensen, K. L. & Overgaard, J., mar. 2000, I: Experimental Oncology. 22, 1-2, s. 32-37 6 s.

Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography—a study evaluating [18F]Fluoro-2-deoxy-D-glucose

Bentzen, L. N., Keiding, S., Horsman, M. R., Falborg, L., Hansen, S. B. & Overgaard, J., 2000, I: Acta Oncologica. 39, 5, s. 629-37 9 s.

Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck

Overgaard, J., Alsner, J., Eriksen, J., Horsman, M. R. & Grau, C., 2000, I: Rays. 25, 3, s. 313-9 7 s.

Non-invasive tumour blood perfusion measurement by 2H magnetic resonance

Bentzen, L. N., Horsman, M. R., Daugaard, P. & Maxwell, R. J., 2000, I: NMR in Biomedicine. 13, 8, s. 429-37 9 s.

Localized in vivo 1H NMR spectroscopy of murine tumours: Effect of blood flow reduction

Nielsen, F. U., Topp, S.-K., Horsman, M. R., Overgaard, J., Stødkilde-Jørgensen, H. & Maxwell, R. J., jun. 1999, I: NMR in Biomedicine. 12, 4, s. 175-83 9 s.

The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo

Ehrnrooth, E., von der Maase, H., Sørensen, B. S., Poulsen, J. H. & Horsman, M. R., 1999, I: International Journal of Radiation Biology. 75, 7, s. 885-91 6 s.

Techniques to assess the oxygenation of human tumors. State of the art

Horsman, M. R., Nordmark, M. & Overgaard, J., dec. 1998, I: Strahlentherapie und Onkologie. 174, Suppl 4, s. 2-5 4 s.

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

Horsman, M. R., Ehrnrooth, E., Ladekar, M. & Overgaard, J., 1 nov. 1998, I: International Journal of Radiation Oncology, Biology, Physics. 42, 4, s. 895-898 4 s.

The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma

Horsman, M. R., Alsner, J. & Overgaard, J., 1998, I: Acta Oncologica. 37, 5, s. 441-5 5 s.

Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing

Horsman, M. R., Siemann, D. W., Chaplin, D. J. & Overgaard, J., nov. 1997, I: Radiotherapy & Oncology. 45, 2, s. 167-74 8 s.

Detection of hypoxic cells in a C3H mouse mammary carcinoma using the comet assay

Olive, P. L., Horsman, M. R., Grau, C. & Overgaard, J., 1 jan. 1997, I: British Journal of Cancer. 76, 6, s. 694-9 6 s.

Can mild hyperthermia improve tumour oxygenation?

Horsman, M. R. & Overgaard, J., 1997, I: International Journal of Hyperthermia. 13, 2, s. 141-7 7 s.

The effect of hypoxia and hyperoxia on nucleoside triphosphate/inorganic phosphate, pO₂ and radiation response in an experimental tumour model

Nordsmark, M., Maxwell, R. J., Horsman, M. R., Bentzen, S. M. & Overgaard, J., 1997, I: British Journal of Cancer. 76, 11, s. 1432-1439 8 s.

Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and ³¹P-magnetic resonance spectroscopy

Nordsmark, M., Maxwell, R. J., Wood, P. J., Stratford, I. J., Adams, G. E., Overgaard, J. & Horsman, M. R., jul. 1996, I: British Journal of Cancer. Supplement. 27, s. S232-S235 4 s.

Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours

Horsman, M. R., Chaplin, D. J., Hill, S. A., Arnold, S., Collingridge, D., Radacic, M., Wood, P. J. & Overgaard, J., jul. 1996, I: British Journal of Cancer. Supplement. 27, s. S168-71 4 s.

Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers

Overgaard, J. & Horsman, M. R., jan. 1996, I: Seminars in Radiation Oncology. 6, 1, s. 10-21 12 s.

A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour

Wood, P. J., Horsman, M. R., Khalil, A. A., Steinberg, F., Streffer, C., Overgaard, J., Stratford, I. J. & Adams, G. E., 1996, I: Acta Oncologica. 35, 8, s. 989-94 6 s.

Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and ³¹P-magnetic resonance spectroscopy
Nordsmark, M., Maxwell, R. J., Wood, P. J., Stratford, I. J., Adams, G. E., Overgaard, J. & Horsman, M. R., 1996, I: British Journal of Cancer. 74, SUPPL. XXVII, s. S232-S235

The in vivo interaction between flavone acetic acid and hyperthermia

Horsman, M. R., Sampson, L. E., Chaplin, D. J. & Overgaard, J., 1996, I: International Journal of Hyperthermia. 12, 6, s. 779-89 11 s.

Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours

Horsman, M. R., Nordsmark, M., Høyer, M. & Overgaard, J., dec. 1995, I: B J C. 72, 6, s. 1474-1478 5 s.

Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model

Nordsmark, M., Grau, C., Horsman, M. R., Jörgensen, H. S. & Overgaard, J., 1 jan. 1995, I: Acta Oncologica. 34, 3, s. 329-34 6 s.

Reoxygenation in a C3H mouse mammary carcinoma. The importance of chronic rather than acute hypoxia

Horsman, M. R., Grau, C. & Overgaard, J., 1 jan. 1995, I: Acta Oncologica. 34, 3, s. 325-8 4 s.

The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma

Horsman, M. R., Khalil, A. A., Chaplin, D. J. & Overgaard, J., 1995, I: Acta Oncologica. 34, 3, s. 443-6 4 s.

The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation

Khalil, A. A., Horsman, M. R. & Overgaard, J., 1995, I: Acta Oncologica. 34, 3, s. 297-300 4 s.

Effect of carbon monoxide breathing on hypoxia and radiation response in the SCCVII tumor in vivo

Grau, C., Nordsmark, M., Khalil, A. A., Horsman, M. R. & Overgaard, J., 15 jun. 1994, I: International Journal of Radiation Oncology, Biology, Physics. 29, 3, s. 449-54 6 s.

Importance of nicotinamide dose on blood pressure changes in mice and humans

Horsman, M. R., Christensen, K. L. & Overgaard, J., 15 jun. 1994, I: International Journal of Radiation Oncology, Biology, Physics. 29, 3, s. 455-8 4 s.

Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation

Horsman, M. R., Khalil, A. A., Siemann, D. W., Grau, C., Hill, S. A., Lynch, E. M., Chaplin, D. J. & Overgaard, J., 15 jun. 1994, I: International Journal of Radiation Oncology, Biology, Physics. 29, 3, s. 439-42 4 s.

The relationship between carbon monoxide breathing, tumour oxygenation and local tumour control in the C3H mammary carcinoma in vivo

Grau, C., Khalil, A. A., Nordmark, M., Horsman, M. R. & Overgaard, J., 1 jan. 1994, I: British Journal of Cancer. 69, 1, s. 50-7 8 s.

Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing

Horsman, M. R., Nordmark, M., Khalil, A. A., Hill, S. A., Chaplin, D. J., Siemann, D. W. & Overgaard, J., 1994, I: Acta Oncologica. 33, 4, s. 371-6 6 s.

The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment

Horsman, M. R., Siemann, D. W., Nordmark, M., Khalil, A. A., Overgaard, J. & Chaplin, D. J., 1994, I: Advances in Experimental Medicine and Biology. 361, s. 635-642 8 s.

Use of tetrahydroindazolone dicarboxylic acid (HIDA) to improve the therapeutic effect in vivo of combined cisplatin, heat and radiation treatment

Overgaard, J., Radacic, M., Skaric, D., Skaric, V., Horsman, M. R., Lindegaard, J. C., Jercic, J. & Lindegaard, J. C., dec. 1993, I: International Journal of Hyperthermia. 9, 6, s. 821-30 10 s.

Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model

Horsman, M. R., Khalil, A. A., Nordmark, M., Grau, C. & Overgaard, J., 1 jul. 1993, I: Radiotherapy & Oncology. 28, 1, s. 69-71 3 s.

Nicotinamide pharmacokinetics in humans and mice: A comparative assessment and the implications for radiotherapy

Horsman, M. R., Høyer, M., Honess, D. J., Dennis, I. F. & Overgaard, J., maj 1993, I: Radiotherapy & Oncology. 27, 2, s. 131-139 9 s.

Reduction of cisplatin-induced renal toxicity in mice by tetrahydroindazolone carboxylic acid (HIDA)

Radacic, M., Overgaard, J., Skaric, D., Skaric, V. & Horsman, M., 1993, I: Acta Oncologica. 32, 1, s. 53-56 4 s.

BW12C-induced changes in haemoglobin-oxygen affinity in mice and its influence on the radiation response of a C3H mouse mammary carcinoma

Horsman, M. R. & Overgaard, J., sep. 1992, I: Radiotherapy & Oncology. 25, 1, s. 43-8 6 s.

Cisplatin and hyperthermia treatment of a C3H mammary carcinoma in vivo. Importance of sequence, interval, drug dose, and temperature

Lindegaard, J. C., Radacic, M., Khalil, A. A., Horsman, M. R. & Overgaard, J., 1 jan. 1992, I: Acta Oncologica. 31, 3, s. 347-351 5 s.

Improving the radiation response in a C3H mouse mammary carcinoma by normobaric oxygen or carbogen breathing

Grau, C., Horsman, M. R. & Overgaard, J., 1 jan. 1992, I: International Journal of Radiation Oncology, Biology, Physics. 22, 3, s. 415-419 5 s.

Influence of carboxyhemoglobin level on tumor growth, blood flow, and radiation response in an experimental model

Grau, C., Horsman, M. R. & Overgaard, J., 1 jan. 1992, I: International Journal of Radiation Oncology, Biology, Physics. 22, 3, s. 421-424 4 s.

Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice
Horsman, M. R., Kristjansen, P. E. G., Mizuno, M., Christensen, K. L., Chaplin, D. J., Quistorff, B. & Overgaard, J., 1992, I: International Journal of Radiation Oncology, Biology, Physics. 22, 3, s. 451-454 4 s.

Overcoming tumour radiation resistance resulting from acute hypoxia
Horsman, M. R. & Overgaard, J., 1992, I: European Journal of Cancer. 28A, 12, s. 2084-5 2 s.

Overcoming tumour radiation resistance resulting from acute hypoxia
Horsman, M. R. & Overgaard, J., 1992, I: European Journal of Cancer. 28A, 4-5, s. 717-718 2 s.

Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure
Horsman, M. R., Christensen, K. L. & Overgaard, J., 1992, I: International Journal of Radiation Oncology, Biology, Physics. 22, 3, s. 455-8 4 s.

The potential of using hyperthermia to eliminate radioresistant hypoxic cells
Overgaard, J., Grau, C., Lindegaard, J. C. & Horsman, M. R., 1 jan. 1991, I: Radiotherapy & Oncology. 20, Suppl 1, s. 113-116 4 s.

Hydralazine-induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues
Fisker, R. V., Horsman, M. R. & Overgaard, J., 1991, I: Acta Oncologica. 30, 5, s. 641-647 7 s.

The effect of combining flavone acetic acid and hyperthermia on the growth of a C3H mammary carcinoma in vivo
Horsman, M. R., Chaplin, D. J. & Overgaard, J., 1991, I: International Journal of Radiation Biology. 60, 1-2, s. 385-388 4 s.

The use of blood flow modifiers to improve the treatment response of solid tumors
Horsman, M. R., Chaplin, D. J. & Overgaard, J., 1991, I: Radiotherapy & Oncology. 20, Suppl 1, s. 47-52 6 s.

Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells
Horsman, M. R., Chaplin, D. J. & Overgaard, J., 1 dec. 1990, I: Cancer Research. 50, 23, s. 7430-7436 7 s.

The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo
Horsman, M. R., Wood, P. J., Chaplin, D. J., Brown, J. & Overgaard, J., maj 1990, I: Radiotherapy & Oncology. 18, 1, s. 49-57 9 s.

Invasive blood pressure measurements in restrained but non-anaesthetized mice
Christensen, K. L., Horsman, M. R. & Overgaard, J., feb. 1990, I: In Vivo. 4, 1, s. 13-16 4 s.

Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status
Horsman, M. R., Hansen, P. V. & Overgaard, J., maj 1989, I: International Journal of Radiation Oncology, Biology, Physics. 16, 5, s. 1273-1276 4 s.

Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy
Horsman, M. R., Overgaard, J., Christensen, K. L., Trotter, M. J. & Chaplin, D. J., 1989, I: Biomedica Biochimica Acta. 48, 2-3, s. S251-4

Mechanism of action of the selective tumor radiosensitizer nicotinamide
Horsman, M. R., Brown, J. M., Hirst, V. K., Lemmon, M. J., Wood, P. J., Dunphy, E. P. & Overgaard, J., sep. 1988, I: International Journal of Radiation Oncology, Biology, Physics. 15, 3, s. 685-690 6 s.

The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay

Horsman, M. R., Overgaard, J. & Chaplin, D. J., 1988, I: Acta Oncologica. 27, 6b, s. 861-2 2 s.

Cell-wall studies of *Pseudomonas aeruginosa* and its carbenicillin-induced L-form [proceedings]

White, C. J. B., Rowe, P. S., Horsman, M. R. & Spicer, A. B., 1977, I: Biochemical Society. Transactions. 5, 5, s. 1496-1498 3 s.